Acute myocardial infarction

12 trials 3 recruiting MedDRA PT
12 Registered trials
3 Recruiting
11 Unique sponsors
16 Unique IMPs
5 Commercial trials
Drug classes (ATC)
V Various (ATC V) 2
— ATC code not specified 5
B Haematology (ATC B) 3
A Gastroenterology (ATC A) 2
C Cardiology (ATC C) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 11 substances
SGLT2 inhibitor 3 substances
Monoclonal antibody 1 substance
Factor Xa inhibitor (DOAC) 1 substance
Phase III: 5 Phase II: 3 Phase IV: 4

Filter these 12 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 12 trials

Phase III

5 trials
  • Celecor Therapeutics Inc. Commercial
    ZALUNFIBAN
    2023-508485-15-00 5 countries 2021 n=2,507
    Ended
  • Novo Nordisk A/S Commercial
    ZILTIVEKIMAB
    2023-506876-28-00 10 countries 2024 n=3,915
    Ended
  • Viatris Innovation GmbH Commercial
    SELATOGREL
    2023-505438-85-00 23 countries 2022 n=13,751
    Recruiting
  • Humanitas Mirasole S.p.A. Academic
    CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN
    2025-523375-29-00 1 country n=300
    Pending
  • Medical University Of Graz Academic
    ICOSAPENT ETHYL
    2024-511950-35-00 3 countries 2025 n=1,758
    Recruiting

Phase II

3 trials
  • Boehringer Ingelheim International GmbH Commercial
    BI 765845; GADOBUTROL
    2022-502788-39-00 7 countries 2023 n=194
    Ended
  • ResoTher Pharma A/S Commercial
    RTP-026 SODIUM
    2023-509182-21-00 2 countries 2024 n=91
    Ended
  • Vaestra Goetalandsregionen Academic
    TICAGRELOR
    2024-514224-17-00 1 country 2021 n=200
    Ended

Phase IV

4 trials
  • Azienda Ospedaliero-Universitaria Maggiore Della Carita Academic
    CANGRELOR TETRASODIUM; TICAGRELOR
    2024-511944-18-01 1 country n=50
    Pending
  • Azienda Ospedaliero-Universitaria Maggiore Della Carita Academic
    DAPAGLIFLOZIN
    2025-521481-10-00 1 country n=140
    Pending
  • Karolinska Institutet Academic
    APIXABAN; PERFLUTREN; SULFUR HEXAFLUORIDE; WARFARIN SODIUM
    2024-514416-28-00 2 countries 2025 n=287
    Recruiting
  • UZ Leuven Academic
    IMP not specified
    2026-525475-96-00 1 country n=160
    Pending
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Azienda Ospedaliero-Universitaria Maggiore Della Carita Academic 2 Phase IV 0
Boehringer Ingelheim International GmbH Commercial 1 Phase II 0
ResoTher Pharma A/S Commercial 1 Phase II 0
Celecor Therapeutics Inc. Commercial 1 Phase III 0
Novo Nordisk A/S Commercial 1 Phase III 0
Viatris Innovation GmbH Commercial 1 Phase III 1
Vaestra Goetalandsregionen Academic 1 Phase II 0
Humanitas Mirasole S.p.A. Academic 1 Phase III 0
Medical University Of Graz Academic 1 Phase III 1
Karolinska Institutet Academic 1 Phase IV 1
UZ Leuven Academic 1 Phase IV 0
New trials by year
2021
2
2022
1
2023
1
2024
2
2025
2
← All indication landscapes